Company Sees $4.5B-$5.0B Operating Cash Flow
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy DGX?
Sees $4.5B-$5.0B operating cash flow, $1.5B-$1.7B capex, $3.0B-$3.3B in free cash flow and about $0.7B in share buybacks. Longer term outlook assumed 7%-9% EPS CAGR and 4%-5% total revenue growth CAGR. Comments taken from investor presentation slides disclosed in regulatory 8-K filing ahead of the company's JP Morgan Health Care Conference presentation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 203.75 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 192.300
Low
190.00
Averages
203.75
High
215.00
Current: 192.300
Low
190.00
Averages
203.75
High
215.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Goldman Sachs Upgrades Futu Holdings to Buy Amid Positive Market Outlook
- Rating Upgrade: Goldman Sachs upgrades Futu Holdings from Neutral to Buy with a target price of $213.39, implying a 29% upside, reflecting a positive outlook on the Chinese wealth management market and a reassessment of Futu's new client growth.
- Market Outlook: Bank of America reiterates its Buy rating on Nvidia with a target price of $275, based on a 28x CY27E PE, indicating Nvidia's leading position in the fast-growing AI compute and networking markets, despite concerns over global AI project volatility and cyclical gaming market issues.
- M&A Potential: Citi upgrades Teck Resources to Buy, highlighting the transformative merger with Anglo American that will create a top-tier copper producer with 80% earnings exposure to copper, showcasing strategic industry consolidation.
- Stock Performance: BTIG upgrades McDonald's to Buy, noting that changes in value and promotions strategy are consistently driving traffic growth, indicating the company's adaptability and growth potential in the competitive fast-food market.
See More
Guardant Health's Optimistic Future Outlook
- Positive Financial Performance: Guardant Health achieved positive free cash flow in Q3 2025, one quarter ahead of its goal, indicating strong growth potential in its core oncology business, with expectations to maintain positive cash flow throughout 2026 and beyond, thereby boosting investor confidence.
- Strategic Collaboration Expansion: The company signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its market position in precision oncology.
- FDA Approval Milestone: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi and Eli Lilly's Erbitux in combination chemotherapy, marking its first FDA approval in colorectal cancer, enhancing the company's competitive edge in the market.
- Optimistic Market Outlook: Although the fourth-quarter financial results for 2025 have yet to be announced, investors maintain an optimistic view of Guardant Health's future, believing that the upcoming update could serve as a catalyst for stock price appreciation, although caution is advised against rushing into purchases in the short term.
See More
Guardant Health Stock Soars Amid New Collaborations
- Stock Performance: Guardant Health's stock has surged over the past six months, currently priced at $110.48 with a market cap of $14 billion, reflecting strong market confidence in its future growth potential.
- Collaboration Agreement: The company has signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its leadership in precision oncology.
- Positive Cash Flow: In Q3 2025, Guardant's core oncology business achieved positive free cash flow ahead of schedule, with management expecting to maintain this trend throughout 2026 and beyond, indicating significant operational efficiency improvements.
- FDA Approval: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi, marking its first FDA certification in colorectal cancer, which, while not impacting Q4 results, lays a solid foundation for future growth.
See More
Quest Diagnostics Named to Fortune's 2026 Most Admired Companies List for 12th Year
- Industry Recognition: Quest Diagnostics has been named to Fortune's Most Admired Companies list for the 12th consecutive year, highlighting the commitment of its 55,000 employees to advancing healthcare and solidifying its leadership position in the industry.
- Category Ranking: The company ranked second in the 'Health Care: Pharmacy and Other Services' category, reflecting its outstanding performance across multiple dimensions such as product quality, innovation, and social responsibility, thereby enhancing its reputation within the sector.
- Reputation Assessment: The recognition is based on evaluations of nearly 700 companies across nine key attributes, including quality of products and services, innovation, and financial profile, showcasing the company's competitive advantages and long-term value in the industry.
- Market Impact: Serving one in three adult Americans and half of the physicians and hospitals in the U.S. annually, Quest Diagnostics' diagnostic insights not only improve health management but also lay a solid foundation for the company's future growth.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Goldman Sachs Upgrades Futu Holdings to Buy Amid Positive Market Outlook
- Rating Upgrade: Goldman Sachs upgrades Futu Holdings from Neutral to Buy with a target price of $213.39, implying a 29% upside, reflecting a positive outlook on the Chinese wealth management market and a reassessment of Futu's new client growth.
- Market Outlook: Bank of America reiterates its Buy rating on Nvidia with a target price of $275, based on a 28x CY27E PE, indicating Nvidia's leading position in the fast-growing AI compute and networking markets, despite concerns over global AI project volatility and cyclical gaming market issues.
- M&A Potential: Citi upgrades Teck Resources to Buy, highlighting the transformative merger with Anglo American that will create a top-tier copper producer with 80% earnings exposure to copper, showcasing strategic industry consolidation.
- Stock Performance: BTIG upgrades McDonald's to Buy, noting that changes in value and promotions strategy are consistently driving traffic growth, indicating the company's adaptability and growth potential in the competitive fast-food market.
See More
Guardant Health's Optimistic Future Outlook
- Positive Financial Performance: Guardant Health achieved positive free cash flow in Q3 2025, one quarter ahead of its goal, indicating strong growth potential in its core oncology business, with expectations to maintain positive cash flow throughout 2026 and beyond, thereby boosting investor confidence.
- Strategic Collaboration Expansion: The company signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its market position in precision oncology.
- FDA Approval Milestone: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi and Eli Lilly's Erbitux in combination chemotherapy, marking its first FDA approval in colorectal cancer, enhancing the company's competitive edge in the market.
- Optimistic Market Outlook: Although the fourth-quarter financial results for 2025 have yet to be announced, investors maintain an optimistic view of Guardant Health's future, believing that the upcoming update could serve as a catalyst for stock price appreciation, although caution is advised against rushing into purchases in the short term.
See More
Guardant Health Stock Soars Amid New Collaborations
- Stock Performance: Guardant Health's stock has surged over the past six months, currently priced at $110.48 with a market cap of $14 billion, reflecting strong market confidence in its future growth potential.
- Collaboration Agreement: The company has signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its leadership in precision oncology.
- Positive Cash Flow: In Q3 2025, Guardant's core oncology business achieved positive free cash flow ahead of schedule, with management expecting to maintain this trend throughout 2026 and beyond, indicating significant operational efficiency improvements.
- FDA Approval: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi, marking its first FDA certification in colorectal cancer, which, while not impacting Q4 results, lays a solid foundation for future growth.
See More
Quest Diagnostics Named to Fortune's 2026 Most Admired Companies List for 12th Year
- Industry Recognition: Quest Diagnostics has been named to Fortune's Most Admired Companies list for the 12th consecutive year, highlighting the commitment of its 55,000 employees to advancing healthcare and solidifying its leadership position in the industry.
- Category Ranking: The company ranked second in the 'Health Care: Pharmacy and Other Services' category, reflecting its outstanding performance across multiple dimensions such as product quality, innovation, and social responsibility, thereby enhancing its reputation within the sector.
- Reputation Assessment: The recognition is based on evaluations of nearly 700 companies across nine key attributes, including quality of products and services, innovation, and financial profile, showcasing the company's competitive advantages and long-term value in the industry.
- Market Impact: Serving one in three adult Americans and half of the physicians and hospitals in the U.S. annually, Quest Diagnostics' diagnostic insights not only improve health management but also lay a solid foundation for the company's future growth.
See More
